|
 |
|
|
|
|
|
|
| |
|
Kidney cancer detection kit - GenoPlex MAP
Multiplex Human Renal Cell Carcinoma Detection Kit
Description
- Multiplex Human Renal Cell Carcinoma Biomarker Panel
Trade Name
Background Information
- GENOMINE Inc. offers the GENOPLEX MAP Human Renal Cell Carcinoma detection kit. The Cancer Biomarker Panel includes Four-Plex assay, which simultaneously measures three serum biomarkers, N-nicotinamide metyltransferase(NNMT), Non-metastatic cells 1(NM23) and L-plastin(LCP). The combination of the four serum biomarkers that discriminate between disease-free and Renal Cell Carcinoma patients was characterized and validated by GENOMINE Inc. and Yonsei University Medical School. Using a scoring algorithm, the profile of three biomarkers in circulation was used to detect all stages of Renal Cell Carcinoma patients with high sensitivity and accuracy. The assays can be used to quantify these biomarkers in serum, plasma, and cell/tissue culture supernatant samples.
Specification
Advantages and Benefits
- Detecting of 3 kidney cancer markers in a single well
- Highly sensitive
- Multiplexing reduces costs and time
- Generates more data with less sample
Clinical Test Results
- Assay : GenoPlex MAP (multiplex human renal cell carcinoma(RCC) biomarker test kit)
- Multiple marker data analysis : logistic regression & ROC
Application
- Screening test for kidney cancer in a high-risk population
- Screening test for Non- high risk population
- Treatment monitoring for post-surgery patients
| |
|
|
|
